Fecal calprotectin and [alpha]1-antitrypsin dynamics in gastrointestinal GvHD
In a previous study, the fecal biomarkers calprotectin and [alpha]1-antitrypsin ([alpha]1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2015-08, Vol.50 (8), p.1105 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 1105 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 50 |
| creator | Dhedin, N de Latour, Rp de Fontbrune, F. Sicre Manene, D Kapel, N Xhaard, A Robin, M O'Meara, A Socie, G |
| description | In a previous study, the fecal biomarkers calprotectin and [alpha]1-antitrypsin ([alpha]1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers calprotectin and [alpha]1-AT throughout the course of GvHD. Patients who were refractory to steroids had initially higher biomarker levels and in the course of GvHD demonstrated a continuous increase in fecal biomarkers. In contrast, the dynamics of calprotectin and [alpha]1-AT demonstrated low and decreasing levels in cortico-sensitive GvHD. In steroid-refractory patients who received a second line of treatment, the biomarker levels at the beginning of second-line treatment did not predict the subsequent response. Nevertheless, calprotectin levels progressively decreased in subsequent responders, whereas non-responders demonstrated continuously high levels of calprotectin. [alpha]1-AT values correlated to a lesser extent with the response to second-line treatment and remained elevated in both non-responders and responders. In conclusion, calprotectin monitoring can be of use in the management of immunosuppressive treatment in GI-GvHD. Bone Marrow Transplantation (2015) 50, 1105-1109; doi: 10.1038/bmt.2015.109; published online 11 May 2015 |
| doi_str_mv | 10.1038/bmt.2015.109 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1701528458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A425675395</galeid><sourcerecordid>A425675395</sourcerecordid><originalsourceid>FETCH-LOGICAL-g878-a844523bf0397d779918819d58b48142b9dbfac962a21950f0a0a021f8e23e1d3</originalsourceid><addsrcrecordid>eNpNj01LAzEQhoMoWKs3f8CC4G1rJh-b5FiqbYWKl95EltndbJuyzdZNKvTfG1CwDMN8PTO8Q8g90AlQrp-qfZwwCjJV5oKMQKgil7yQl2REWaFzzgtzTW5C2FEKQlA5Im9zW2OXJT8MfbR1dD5D32QfqbHFT8jRRxeH0yGkQXPyuHd1yFK-wRCH3vloQ9pJJxbfy-dbctViF-zdXxyT9fxlPVvmq_fF62y6yjda6Ry1EJLxqqXcqEYpY0BrMI3UldAgWGWaqsXaFAwZGElbiskYtNoybqHhY_LwezZp_jomAeWuPw5JRChBpf-ZFlL_UxvsbOl828cB670LdTkVTBZKciMT9XhGbS12cRv67hhd78M5-APQM2cO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1701528458</pqid></control><display><type>article</type><title>Fecal calprotectin and [alpha]1-antitrypsin dynamics in gastrointestinal GvHD</title><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Dhedin, N ; de Latour, Rp ; de Fontbrune, F. Sicre ; Manene, D ; Kapel, N ; Xhaard, A ; Robin, M ; O'Meara, A ; Socie, G</creator><creatorcontrib>Dhedin, N ; de Latour, Rp ; de Fontbrune, F. Sicre ; Manene, D ; Kapel, N ; Xhaard, A ; Robin, M ; O'Meara, A ; Socie, G</creatorcontrib><description>In a previous study, the fecal biomarkers calprotectin and [alpha]1-antitrypsin ([alpha]1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers calprotectin and [alpha]1-AT throughout the course of GvHD. Patients who were refractory to steroids had initially higher biomarker levels and in the course of GvHD demonstrated a continuous increase in fecal biomarkers. In contrast, the dynamics of calprotectin and [alpha]1-AT demonstrated low and decreasing levels in cortico-sensitive GvHD. In steroid-refractory patients who received a second line of treatment, the biomarker levels at the beginning of second-line treatment did not predict the subsequent response. Nevertheless, calprotectin levels progressively decreased in subsequent responders, whereas non-responders demonstrated continuously high levels of calprotectin. [alpha]1-AT values correlated to a lesser extent with the response to second-line treatment and remained elevated in both non-responders and responders. In conclusion, calprotectin monitoring can be of use in the management of immunosuppressive treatment in GI-GvHD. Bone Marrow Transplantation (2015) 50, 1105-1109; doi: 10.1038/bmt.2015.109; published online 11 May 2015</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2015.109</identifier><language>eng</language><publisher>London: Nature Publishing Group</publisher><subject>Alpha 1-antitrypsin ; Bone marrow ; Complications and side effects ; Drug therapy ; Graft vs. host disease ; Health aspects ; Hematopoietic stem cell transplantation ; Risk factors ; Stem cell transplantation</subject><ispartof>Bone marrow transplantation (Basingstoke), 2015-08, Vol.50 (8), p.1105</ispartof><rights>COPYRIGHT 2015 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Aug 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Dhedin, N</creatorcontrib><creatorcontrib>de Latour, Rp</creatorcontrib><creatorcontrib>de Fontbrune, F. Sicre</creatorcontrib><creatorcontrib>Manene, D</creatorcontrib><creatorcontrib>Kapel, N</creatorcontrib><creatorcontrib>Xhaard, A</creatorcontrib><creatorcontrib>Robin, M</creatorcontrib><creatorcontrib>O'Meara, A</creatorcontrib><creatorcontrib>Socie, G</creatorcontrib><title>Fecal calprotectin and [alpha]1-antitrypsin dynamics in gastrointestinal GvHD</title><title>Bone marrow transplantation (Basingstoke)</title><description>In a previous study, the fecal biomarkers calprotectin and [alpha]1-antitrypsin ([alpha]1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers calprotectin and [alpha]1-AT throughout the course of GvHD. Patients who were refractory to steroids had initially higher biomarker levels and in the course of GvHD demonstrated a continuous increase in fecal biomarkers. In contrast, the dynamics of calprotectin and [alpha]1-AT demonstrated low and decreasing levels in cortico-sensitive GvHD. In steroid-refractory patients who received a second line of treatment, the biomarker levels at the beginning of second-line treatment did not predict the subsequent response. Nevertheless, calprotectin levels progressively decreased in subsequent responders, whereas non-responders demonstrated continuously high levels of calprotectin. [alpha]1-AT values correlated to a lesser extent with the response to second-line treatment and remained elevated in both non-responders and responders. In conclusion, calprotectin monitoring can be of use in the management of immunosuppressive treatment in GI-GvHD. Bone Marrow Transplantation (2015) 50, 1105-1109; doi: 10.1038/bmt.2015.109; published online 11 May 2015</description><subject>Alpha 1-antitrypsin</subject><subject>Bone marrow</subject><subject>Complications and side effects</subject><subject>Drug therapy</subject><subject>Graft vs. host disease</subject><subject>Health aspects</subject><subject>Hematopoietic stem cell transplantation</subject><subject>Risk factors</subject><subject>Stem cell transplantation</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpNj01LAzEQhoMoWKs3f8CC4G1rJh-b5FiqbYWKl95EltndbJuyzdZNKvTfG1CwDMN8PTO8Q8g90AlQrp-qfZwwCjJV5oKMQKgil7yQl2REWaFzzgtzTW5C2FEKQlA5Im9zW2OXJT8MfbR1dD5D32QfqbHFT8jRRxeH0yGkQXPyuHd1yFK-wRCH3vloQ9pJJxbfy-dbctViF-zdXxyT9fxlPVvmq_fF62y6yjda6Ry1EJLxqqXcqEYpY0BrMI3UldAgWGWaqsXaFAwZGElbiskYtNoybqHhY_LwezZp_jomAeWuPw5JRChBpf-ZFlL_UxvsbOl828cB670LdTkVTBZKciMT9XhGbS12cRv67hhd78M5-APQM2cO</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Dhedin, N</creator><creator>de Latour, Rp</creator><creator>de Fontbrune, F. Sicre</creator><creator>Manene, D</creator><creator>Kapel, N</creator><creator>Xhaard, A</creator><creator>Robin, M</creator><creator>O'Meara, A</creator><creator>Socie, G</creator><general>Nature Publishing Group</general><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20150801</creationdate><title>Fecal calprotectin and [alpha]1-antitrypsin dynamics in gastrointestinal GvHD</title><author>Dhedin, N ; de Latour, Rp ; de Fontbrune, F. Sicre ; Manene, D ; Kapel, N ; Xhaard, A ; Robin, M ; O'Meara, A ; Socie, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g878-a844523bf0397d779918819d58b48142b9dbfac962a21950f0a0a021f8e23e1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Alpha 1-antitrypsin</topic><topic>Bone marrow</topic><topic>Complications and side effects</topic><topic>Drug therapy</topic><topic>Graft vs. host disease</topic><topic>Health aspects</topic><topic>Hematopoietic stem cell transplantation</topic><topic>Risk factors</topic><topic>Stem cell transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhedin, N</creatorcontrib><creatorcontrib>de Latour, Rp</creatorcontrib><creatorcontrib>de Fontbrune, F. Sicre</creatorcontrib><creatorcontrib>Manene, D</creatorcontrib><creatorcontrib>Kapel, N</creatorcontrib><creatorcontrib>Xhaard, A</creatorcontrib><creatorcontrib>Robin, M</creatorcontrib><creatorcontrib>O'Meara, A</creatorcontrib><creatorcontrib>Socie, G</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhedin, N</au><au>de Latour, Rp</au><au>de Fontbrune, F. Sicre</au><au>Manene, D</au><au>Kapel, N</au><au>Xhaard, A</au><au>Robin, M</au><au>O'Meara, A</au><au>Socie, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fecal calprotectin and [alpha]1-antitrypsin dynamics in gastrointestinal GvHD</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><date>2015-08-01</date><risdate>2015</risdate><volume>50</volume><issue>8</issue><spage>1105</spage><pages>1105-</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>In a previous study, the fecal biomarkers calprotectin and [alpha]1-antitrypsin ([alpha]1-AT) at symptom onset were reported to be significantly associated with the response to steroids in gastrointestinal GvHD (GI-GvHD). The purpose of this trial was to evaluate the dynamics of the fecal biomarkers calprotectin and [alpha]1-AT throughout the course of GvHD. Patients who were refractory to steroids had initially higher biomarker levels and in the course of GvHD demonstrated a continuous increase in fecal biomarkers. In contrast, the dynamics of calprotectin and [alpha]1-AT demonstrated low and decreasing levels in cortico-sensitive GvHD. In steroid-refractory patients who received a second line of treatment, the biomarker levels at the beginning of second-line treatment did not predict the subsequent response. Nevertheless, calprotectin levels progressively decreased in subsequent responders, whereas non-responders demonstrated continuously high levels of calprotectin. [alpha]1-AT values correlated to a lesser extent with the response to second-line treatment and remained elevated in both non-responders and responders. In conclusion, calprotectin monitoring can be of use in the management of immunosuppressive treatment in GI-GvHD. Bone Marrow Transplantation (2015) 50, 1105-1109; doi: 10.1038/bmt.2015.109; published online 11 May 2015</abstract><cop>London</cop><pub>Nature Publishing Group</pub><doi>10.1038/bmt.2015.109</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2015-08, Vol.50 (8), p.1105 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_journals_1701528458 |
| source | SpringerLink Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Alpha 1-antitrypsin Bone marrow Complications and side effects Drug therapy Graft vs. host disease Health aspects Hematopoietic stem cell transplantation Risk factors Stem cell transplantation |
| title | Fecal calprotectin and [alpha]1-antitrypsin dynamics in gastrointestinal GvHD |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T08%3A53%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fecal%20calprotectin%20and%20%5Balpha%5D1-antitrypsin%20dynamics%20in%20gastrointestinal%20GvHD&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Dhedin,%20N&rft.date=2015-08-01&rft.volume=50&rft.issue=8&rft.spage=1105&rft.pages=1105-&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2015.109&rft_dat=%3Cgale_proqu%3EA425675395%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1701528458&rft_id=info:pmid/&rft_galeid=A425675395&rfr_iscdi=true |